Although Not Improving DFS, Adjuvant Avelumab May Potentially Reduce the Risk of Death in Patients with High-Risk TNBC By Ogkologos - September 9, 2025 556 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the A-BRAVE study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer MOST POPULAR PFS Non-inferior with Fixed-Duration Treatment with Venetoclax-Obinutuzumab or Venetoclax-Ibrutinib to Continuous... December 17, 2025 Professor Eithne Costello: On the road to early detection November 12, 2021 Seeing a Promising Future for Progress against Childhood Cancer September 16, 2021 Honeybee Venom May Be the Next Treatment for Aggressive Breast Cancer September 2, 2020 Load more HOT NEWS New “Microwave Mammography” Promises to be Safer, More Accurate, and Pain-Free An existing blood test for ovarian cancer has been re-evaluated. The... Finding Purpose During Cancer: A Survivor’s Story A Personalised Prediction Model Based on Clinical and Genomic Data Outperforms...
